Department of Biochemistry and Medical Chemistry, Pomeranian Medical University in Szczecin, Al. Powstańców Wielkopolskich 72, 70-111, Szczecin, Poland.
Department of Psychiatry, Pomeranian Medical University in Szczecin, ul Broniewskiego 26, 71-460, Szczecin, Poland.
Lipids Health Dis. 2019 Apr 4;18(1):85. doi: 10.1186/s12944-019-1040-5.
Lysophosphatidic acid (LPA) and lysophosphatidylcholine (LPC) are bioactive lysophospholipids involved in the pathogenesis of renal diseases, especially the renal fibrosis. Plasma LPC concentrations in chronic kidney disease (CKD) patients are lower or similar to those observed in control groups, but less is known about the LPA concentrations. The main aim of the study was the analysis of associations of chronic kidney disease and renal replacement therapy with the plasma LPA concentrations. We have also analyzed the relationship between the plasma concentrations of LPA and LPC.
Study group consisted of 110 patients with CKD in stages G3-G5 according to the KDIGO guidelines and was divided into four subgroups: treated conservatively (CT, 30 patients), on hemodialysis (HD, 30 patients), on peritoneal dialysis (PD, 30 patients) and renal transplant recipients (RT, 20 patients). In HD the blood was collected immediately before (HD D1) and after the dialysis (HD D2). In RT the blood was collected immediately before (RT D1) and 3-14 days after the transplantation (RT D2). The control group (Con) consisted of 50 healthy volunteers. Plasma concentrations of LPA and LPC were measured using enzyme-linked immunosorbent assays.
In CT, PD and RT D2 plasma concentrations of LPA were significantly higher, compared to Con. In HD, LPA levels did not differ compared to Con and they were significantly lower compared to PD (HD D1 and HD D2), RT D2 (HD D1 and HD D2) and CT (HD D1). However, in most of patients concentrations of LPA were within the range of reference values established in healthy volunteers. Concentrations of LPC were significantly lower in almost all patients subgroups, compared to Con, except in PD. There were no significant correlations between plasma concentrations of LPA and LPC in any of patients subgroups.
Presence of CKD is associated with increased plasma LPA levels and the hemodialysis therapy reduces this influence. However, only in a small percentage of patients with CKD, LPA concentrations are out of the reference range, which makes LPA not useful as a diagnostic marker for CKD. Further studies are needed to confirm and explain observed relationships.
溶血磷脂酸（LPA）和溶血磷脂酰胆碱（LPC）是参与肾脏疾病发病机制的生物活性溶血磷脂，尤其是肾纤维化。慢性肾脏病（CKD）患者的血浆 LPC 浓度较低或与对照组相似，但对 LPA 浓度知之甚少。本研究的主要目的是分析慢性肾脏病和肾脏替代治疗与血浆 LPA 浓度的关系。我们还分析了 LPA 和 LPC 血浆浓度之间的关系。
研究组由根据 KDIGO 指南处于 G3-G5 期的 110 例 CKD 患者组成，分为四个亚组：保守治疗（CT，30 例）、血液透析（HD，30 例）、腹膜透析（PD，30 例）和肾移植受者（RT，20 例）。在 HD 中，血液在透析前（HD D1）和透析后（HD D2）采集。在 RT 中，血液在移植前（RT D1）和移植后 3-14 天（RT D2）采集。对照组（Con）由 50 名健康志愿者组成。使用酶联免疫吸附试验测量 LPA 和 LPC 的血浆浓度。
在 CT、PD 和 RT D2 中，LPA 的血浆浓度明显高于 Con。在 HD 中，与 Con 相比，LPA 水平没有差异，与 PD（HD D1 和 HD D2）、RT D2（HD D1 和 HD D2）和 CT（HD D1）相比，LPA 水平明显降低。然而，在大多数患者中，LPA 的浓度在健康志愿者建立的参考值范围内。与 Con 相比，除 PD 外，几乎所有患者亚组的 LPC 浓度均显著降低。在任何患者亚组中，LPA 和 LPC 的血浆浓度之间均无显著相关性。
CKD 的存在与血浆 LPA 水平升高有关，血液透析治疗降低了这种影响。然而，只有一小部分 CKD 患者的 LPA 浓度超出参考范围，这使得 LPA 不能作为 CKD 的诊断标志物。需要进一步的研究来证实和解释观察到的关系。
